How β3 -adrenoceptor-selective is mirabegron?

Affiliations

Comment

Martin C Michel. Br J Pharmacol. 2016 Feb.

. 2016 Feb;173(3):429-30.

doi: 10.1111/bph.13379.

No abstract available

Comment on

Mirabegron relaxes urethral smooth muscle by a dual mechanism involving β3 -adrenoceptor activation and α1 -adrenoceptor blockade.
Alexandre EC, Kiguti LR, Calmasini FB, Silva FH, da Silva KP, Ferreira R, Ribeiro CA, Mónica FZ, Pupo AS, Antunes E. Alexandre EC, et al. Br J Pharmacol. 2016 Feb;173(3):415-28. doi: 10.1111/bph.13367. Epub 2016 Jan 15. Br J Pharmacol. 2016. PMID: 26493129 Free PMC article.

1. Alexandre EC, Kiguti LR, Calmasini FB, Silva FH, da Silva KP, Ferreira R et al (2016). Mirabegron relaxes urethral smooth muscle by a dual mechanism involving β3‐adrenoceptor activation and α1‐adrenoceptor blockade. Br J Pharmacol 173: 415–428. - PMC - PubMed
1. Ichihara K, Masumori N, Fukuta F, Tsukamoto T, Iwasawa A, Tanaka Y (2015). A randomized controlled study of the efficacy of tamsulosin monotherapy and its combination with mirabegron for overactive bladder induced by benign prostatic obstruction. J Urol 193: 921–926. - PubMed
1. Igawa Y, Michel MC (2013). Pharmacological profile of β3‐adrenoceptor agonists in clinical development for the treatment of overactive bladder syndrome. Naunyn‐Schmiedeberg's Arch Pharmacol 386: 177–183. - PubMed
1. Krauwinkel W, van Dijk J, Schaddelee M, Eltink C, Meijer J, Strabach G et al (2012). Pharmacokinetic properties of mirabegron, a β3‐adrenoceptor agonist: results from two phase I, randomized, multiple‐dose studies in healthy young and elderly men and women. Clin Ther 34: 2144–2160. - PubMed
1. Levay M, Krobert KA, Wittig K, Voigt N, Bermudez M, Wolber G et al (2013). NSC23766, a widely used inhibitor of Rac1 activation, additionally acts as a competitive antagonist at muscarinic acetylcholine receptors. J Pharmacol Exp Ther 347: 69–79. - PubMed